Promising new vaccines are designed to be given to patients at risk of developing Alzheimer’s disease. Graham Lawton New Scientist If they...
Vous n'êtes pas connecté
Eli Lilly’s Alzheimer’s therapy, donanemab, has received FDA approval, offering new hope for patients with early symptomatic Alzheimer’s disease. The newly approved treatment, branded Kisunla, is set to challenge existing therapies from Eisai and Biogen. Clinical trials have shown Kisunla to be effective for individuals in the mild cognitive impairment or mild dementia stages of […]
Promising new vaccines are designed to be given to patients at risk of developing Alzheimer’s disease. Graham Lawton New Scientist If they...
New research from the University of Kentucky’s Sanders-Brown Center on Aging has revealed that the cognitive impairments seen in long COVID patients...
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September...
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
WEDNESDAY, Aug. 28, 2024 -- Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study...
New research has found a way to diagnose Alzheimer’s disease (AD) earlier by analyzing biomarkers in blood. This could help reduce the effects of...
Cognitive behavioral therapy, one of the most common treatments for depression, can teach skills for coping with everyday troubles, reinforce healthy...
Cognitive behavioral therapy, one of the most common treatments for depression, can teach skills for coping with everyday troubles, reinforce healthy...
Eli Lilly will now sell cheaper vials of Zepbound, presenting a direct challenge to telehealth companies that offer compounded versions of the...
Cognitive decline and dementia can be caused by illnesses like Alzheimer’s disease and conditions like high blood pressure, which damage blood...